MIR192

Summary

MIR192 (microRNA 192, HGNC:31562) is a microRNA gene on chromosome 11q13.1.

microRNAs (miRNAs) are short (20-24 nt) non-coding RNAs that are involved in post-transcriptional regulation of gene expression in multicellular organisms by affecting both the stability and translation of mRNAs. miRNAs are transcribed by RNA polymerase II as part of capped and polyadenylated primary transcripts (pri-miRNAs) that can be either protein-coding or non-coding. The primary transcript is cleaved by the Drosha ribonuclease III enzyme to produce an approximately 70-nt stem-loop precursor miRNA (pre-miRNA), which is further cleaved by the cytoplasmic Dicer ribonuclease to generate the mature miRNA and antisense miRNA star (miRNA*) products. The mature miRNA is incorporated into a RNA-induced silencing complex (RISC), which recognizes target mRNAs through imperfect base pairing with the miRNA and most commonly results in translational inhibition or destabilization of the target mRNA. The RefSeq represents the predicted microRNA stem-loop.

Source: NCBI Gene 406967 — RefSeq curated summary.

At a glance

• Gene type: non-coding (miRNA) — no protein product; not a drug target. Variant/disease associations are omitted (they would be positional, from an overlapping protein-coding gene).

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:31562
Approved symbol	MIR192
Name	microRNA 192
Location	11q13.1
Locus type	RNA, micro
Status	Approved
Aliases	hsa-mir-192
Ensembl gene	ENSG00000283926
Ensembl biotype	miRNA
OMIM	610939
Entrez	406967
RNAcentral	URS00006ECF62 — miRNA, 110 nt, 6 organism(s)

Gene structure

Transcript identifiers

Ensembl transcripts: 1 — 1 miRNA

ENST00000384915

RefSeq mRNA: 0 — MANE Select: None

Canonical transcript exons

ENST00000384915 — 1 exons

Exon	Start	End
ENSE00001499922	64891137	64891246

Expression profiles

Bgee: expression breadth broad, 45 present calls, max score 83.54.

Top tissues by expression

45 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
duodenum	UBERON:0002114	83.54	gold quality
small intestine	UBERON:0002108	75.98	gold quality
vermiform appendix	UBERON:0001154	75.48	gold quality
islet of Langerhans	UBERON:0000006	75.21	gold quality
small intestine Peyer’s patch	UBERON:0003454	74.72	gold quality
intestine	UBERON:0000160	73.97	gold quality
lymph node	UBERON:0000029	72.70	gold quality
right lobe of liver	UBERON:0001114	72.23	gold quality
transverse colon	UBERON:0001157	72.13	gold quality
colon	UBERON:0001155	71.47	gold quality
blood	UBERON:0000178	70.73	gold quality
ascending aorta	UBERON:0001496	70.33	gold quality
gastrocnemius	UBERON:0001388	69.67	gold quality
body of pancreas	UBERON:0001150	69.19	gold quality
left adrenal gland	UBERON:0001234	69.02	gold quality
tibial nerve	UBERON:0001323	68.78	gold quality
stomach	UBERON:0000945	68.65	gold quality
body of stomach	UBERON:0001161	68.15	gold quality
omental fat pad	UBERON:0010414	67.96	gold quality
hypothalamus	UBERON:0001898	67.65	gold quality
skin of abdomen	UBERON:0001416	67.12	gold quality
left coronary artery	UBERON:0001626	66.93	gold quality
kidney	UBERON:0002113	66.49	gold quality
esophagus mucosa	UBERON:0002469	65.72	gold quality
pituitary gland	UBERON:0000007	65.71	gold quality
spleen	UBERON:0002106	65.52	gold quality
multicellular organism	UBERON:0000468	65.38	gold quality
Brodmann (1909) area 9	UBERON:0013540	65.33	gold quality
right atrium auricular region	UBERON:0006631	64.83	gold quality
adult mammalian kidney	UBERON:0000082	64.40	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): ETS1, PAX1, TP53

Literature-anchored findings (GeneRIF, showing 40)

• Results showing a role for miR-192/215 in cell proliferation combined with recent observations that these miRNAs are underexpressed in primary cancers support the idea that miR-192 and miR-215 function as tumor suppressors. (PMID:19074876)
• miR-192 may be another miRNA candidate that is involved in the p53 tumor suppressor network with significant effect on cell cycle control and cell proliferation. (PMID:19088023)
• loss of miR-192 expression associates with increased fibrosis and decreased estimated glomerular filtration rate in diabetic nephropathy in vivo (PMID:20056746)
• miR-192 and miR-215 target thymidylate synthase expression in colorectal cancer cell lines. (PMID:20647341)
• in gastric cancer, both microRNA-192 and -215 are overexpressed in vivo and exert cell growth and migration-promoting effects in vitro. (PMID:21119604)
• serum and urinary levels lower in systemic lupus erythematosus patients than in controls (PMID:21372198)
• Analysis of miRNA expression in clinical samples showed that miR-192 is significantly downregulated in lung cancer tissues compared to adjacent non-cancerous lung tissues. (PMID:21511813)
• These results indicated that persistent HBV infection might trigger NER impairment in part through upregulation of miR-192, which suppressed the levels of ERCC3 and ERCC4. (PMID:21672525)
• Data show that Differentially expressed miRNAs including miR-99a, miR-100, miR-125b, miR-192, and miR-429 were detected in pancreatic cancer stem cells. (PMID:21785383)
• Down-regulation of MIRN192 is associated with gastric carcinoma. (PMID:22205577)
• study identify co-ordinated regulation of miR-192 and miR-194, with binding of hepatocyte nuclear factor and p53 transcription factors necessary for activation of transcription (PMID:22264233)
• HBx could inhibit apoptosis of HepG2 cells through down-regulation of miR-192. (PMID:22433310)
• the miRNA profile in peripheral blood was altered after allergen inhalation challenge. Change in miR-192 levels may be implicated in asthma mechanisms (PMID:23170939)
• Overexpression of miR-192 contributes to tumor growth and progression in Pancreatic ductal adenocarcinoma, which is associated with repression of SIP1 and alteration of cell cycle regulatory genes. (PMID:23612862)
• The pretherapeutic intratumoral expression of miR-192 and miR-194 was significantly associated with the histopathologic response of esophageal squamous cell carcinoma to multimodal therapeutic treatment. (PMID:23649428)
• we showed that miR-192, miR-194 and miR-215 have tumor suppressor effects on RCC by reducing the cellular migration and invasion abilities. (PMID:23715501)
• During prolonged TGF-beta treatment, p300 acetylated histone and Ets-1, resulting in complete dissociation of Ets-1 and the opening of the chromatin for sustained miR-192 expression (PMID:23737550)
• inhibition of Akt or ectopic expression of dominant-negative histone acetyltransferases decreased p300-mediated acetylation and Ets-1 dissociation from the miR-192 promoter and prevented miR-192 expression in response to TGF-beta (PMID:23737551)
• Both miR-194 and miR-34a microRNAs are coordinately increased with miR-192, particularly in exosomes, suggesting that these microRNAs function as circulating regulators of heart failure development via the p53 pathway. (PMID:23743335)
• Loss of microRNA-192 expression is associated with breast cancer. (PMID:24012720)
• Findings indicate that miR-192 has an important role in colon cancer development and progression. (PMID:24213572)
• Data suggest that miR-192 might be a key player in neuroblastoma (NB) by regulating Dicer1 expression. (PMID:24223844)
• data demonstrate a core role for miR-192 in mediating proximal tubular epithelial cell G2/M arrest after toxic injury by aristolochic acid. (PMID:24508230)
• Overexpression of either miR-192 or miR-30c in enterocyte and hepatocyte cells suggested an effect on the expression of genes related to lipid metabolism. (PMID:24623846)
• In colorectal adenomatous polyps, the expression of miR-320a increased and miR-145 and miR-192 expression decreased with higher histologic grade. (PMID:24791633)
• MiR-192 binded to Bim 3’-UTR and negatively regulated Bim expression at the post-transcriptional level in lung adenocarcinoma cells. (PMID:24854555)
• frequently up-regulated miR-215/192 in gastric cancer may participate in gastric cancer progression (PMID:24981590)
• Using a blood test based on detection of serum miRNAs that distinguishes early NSCLC patients from healthy volunteers, miR-17, 21 and 192 expression levels were found to be significantly higher in the stage I NSCLC patients than the healthy volunteers. (PMID:25146671)
• miR-192 and miR-193b abundance are increased in the prediabetic state and in glucose-intolerant mice. Circulating levels of miR-192 and miR-193b return to baseline in both prediabetic humans and glucose-intolerant mice undergoing chronic exercise. (PMID:25532038)
• these data suggest that miR-192 may be a suppressor for bladder cancer cells by cell cycle regulation. (PMID:25566965)
• The MiR-192 (and MiR-215) pathway was found to play an important role in the pathogenesis of Hirschsprung’s disease. (PMID:25857602)
• miR-192 directly targeted 3’-UTR of Bim gene, and inhibited its protein expression in esophageal squamous carcinoma cells, suppressing apoptosis and promoting proliferation. (PMID:26339371)
• Multivariate logistic analysis revealed a panel of four microRNAs (miR-19a, miR-195, miR-192, and miR-146a) with high diagnostic accuracy for hepatocellular carcinoma (AUC = 0.946). (PMID:26352740)
• miR-192 suppresses leptomeningeal dissemination of medulloblastoma by modulating cell proliferation and anchoring ability. (PMID:26506238)
• microRNAs -122, -192 and -21 are expressed in serum of patients with non-alcoholic steatohepatitis (PMID:26565986)
• this study shows that microRNA-192-5p promote the proliferation and metastasis of hepatocellular carcinoma cell by targeting SEMA3A (PMID:26580097)
• Our study via modeling in combination with quantitative experiments provides new evidence on the role of microRNA-mediated positive feedback loops in conferring robustness to the system performance of stress-induced response of p53. (PMID:26642352)
• Downregulation of microRNA-192 is associated with hepatocellular carcinoma. (PMID:26684241)
• miR-192 suppresses HOTTIP expression thereby inhibiting HCC growth in vitro and in vivo. (PMID:26710269)
• we suggest that targeting miR-192 and NOB1 is a novel strategy which will assist in the development of new therapeutics that will be used in the future to prevent and treat prostate cancer. (PMID:26743688)

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
mus_musculus	Mir192	ENSMUSG00000065523
rattus_norvegicus	Mir192	ENSRNOG00000035530

Protein

Non-coding RNA — no protein product; not a drug target.

Function

No curated pathway, Gene-Ontology, or interaction data.

Disease & clinical

No curated disease, variant, or cancer-driver associations.

Drugs & pharmacology

No drug or pharmacology data — not an established drug target.